Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice

Ciolek, A. M., Arnall, J., Moore, D. C., Palkimas, S., Der-Nigoghossian, J., & Dane, K. (2021). Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice. Annals of Pharmacotherapy, 56(7), 831–838. https://doi.org/10.1177/10600280211049394
Authors:
Alana M Ciolek
Justin Arnall
Donald C Moore
Surabhi Palkimas
Julie Der-Nigoghossian
Kathryn Dane
Affiliated Authors:
Alana M Ciolek
Subjects:
Factor VIIa (MeSH)
Hemophilia A (MeSH)
Hemophilia B (MeSH)
Author Keywords:
feiba
novoseven
sevenfact
bypassing agent
hemophilia
inhibitors
recombinant factor vii
elink
Publication Type:
Article
Unique ID:
10.1177/10600280211049394
PMID:
34595941
DOI:
10.1177/10600280211049394
Journal:
Annals of Pharmacotherapy
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: